Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
622 Immune phenotype and iFRET functional analysis are biomarkers of response to neoadjuvant intralesional therapy for high risk stage II melanoma
Compose a Response to This Article
Other responses
No responses have been published for this article.
